Search

Your search keyword '"Zijlstra, Josée M"' showing total 656 results
Start Over Author "Zijlstra, Josée M"
656 results on '"Zijlstra, Josée M"'

3. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Author

Fuchs, Michael, Jacob, Anne Sophie, Kaul, Helen, Kobe, Carsten, Kuhnert, Georg, Pabst, Thomas, Greil, Richard, Bröckelmann, Paul J., Topp, Max S., Just, Marianne, Hertenstein, Bernd, Soekler, Martin, Vogelhuber, Martin, Zijlstra, Josée M., Keller, Ulrich Bernd, Krause, Stefan W., Dührsen, Ulrich, Meissner, Julia, Viardot, Andreas, Eich, Hans-Theodor, Baues, Christian, Diehl, Volker, Rosenwald, Andreas, Buehnen, Ina, von Tresckow, Bastian, Dietlein, Markus, Borchmann, Peter, Engert, Andreas, and Eichenauer, Dennis A.

Published
2024
Full Text
View/download PDF

4. Active Patient Participation in the Development of an Online Intervention

Author

van Bruinessen, Inge Renske, van Weel-Baumgarten, Evelyn M, Snippe, Harm Wouter, Gouw, Hans, Zijlstra, Josée M, and van Dulmen, Sandra

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundAn important and challenging part of living with cancer relates to the repeated visits to the hospital. Since how patients cope between these post-diagnostic visits depends partly on the information and support received from their physician during the visits, it is important to make the most of them. Recent findings reinforce the importance of training not only the health care professionals in communication skills, but providing patients with support in communication as well. Delivering such supportive interventions online can have potential benefits in terms of accessibility, cost-effectiveness, and ability to tailor information to personal needs. However, problems with attrition (dropout, non-usage) during the test phase and poor uptake after implementation are frequently reported. The marginal level of engagement of the patient as end user seems to play a role in this. Therefore, recent research suggests integrating theory-based development methods with methods that promote involvement of the patient at an early stage. This paper describes a participatory protocol, used to let patients guide a theory-informed development process. ObjectiveThe objective of this project was to apply a bottom-up inspired procedure to develop a patient-centered intervention with corresponding evaluation and implementation plan. MethodsThe applied development protocol was based on the intervention mapping framework, combined with patient participatory methods that were inspired by the participation ladder and user-centred design methods. ResultsThe applied protocol led to a self-directed online communication intervention aimed at helping patients gain control during their communications with health care professionals. It also led to an evaluation plan and an implementation plan. The protocol enabled the continuous involvement of patient research partners and the partial involvement of patient service users, which led to valuable insights and improvements. ConclusionsThe applied protocol realized patient participation on different levels throughout the entire project. Early involvement, involvement on different levels, and flexibility in terms of planning and setup seem to be preconditions to creating a bottom-up inspired development procedure with (seriously ill) patients. Further research is necessary to find out if a more patient-centered approach improves the implementation and uptake of eHealth interventions. Trial RegistrationNetherlands National Trial Register ID number: NTR3779; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3779 (Archived by WebCite at http://www.webcitation.org/6TdfALKxV).

Published
2014
Full Text
View/download PDF

5. Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

Author

de Groot, Fleur A., Dekker, Tim J.A., Doorduijn, Jeanette K., Böhringer, Stefan, Brink, Mirian, de Groen, Ruben A.L., de Haan, Lorraine M., Woei-A-Jin, F.J. Sherida H., Noordenbos, Troy, Sijs-Szabo, Aniko, Oudshoorn, Mirjam A., Lam, King H., Diepstra, Arjan, te Boome, Liane C.J., Terpstra, Valeska, Bohmer, Lara H., Nicolae, Alina, Posthuma, Eduardus F.M., Koens, Lianne, Durian, Marc F., Stavast, Jeroen, van der Poel, Marjolein W.M., Hamid, Myrurgia Abdul, Stevens, Wendy B.C., van Rooij, Sjo L.M., Oostvogels, Rimke S., Mühlebner, Angelika, Neelis, Karen J., van den Brand, Michiel, Tousseyn, Thomas, Dierickx, Daan, de Weerdt, Okke, Beeker, Aart, Jansen, Patty M., Kersten, Marie José, Zijlstra, Josée M., Chamuleau, Martine E.D., Veelken, Hendrik, Bromberg, Jacoline C.E., Nijland, Marcel, and Vermaat, Joost S.P.

Published
2024
Full Text
View/download PDF

6. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Author

Borchmann, Peter, Ferdinandus, Justin, Schneider, Gundolf, Moccia, Alden, Greil, Richard, Hertzberg, Mark, Schaub, Valdete, Hüttmann, Andreas, Keil, Felix, Dierlamm, Judith, Hänel, Mathias, Novak, Urban, Meissner, Julia, Zimmermann, Andreas, Mathas, Stephan, Zijlstra, Josée M, Fosså, Alexander, Viardot, Andreas, Hertenstein, Bernd, Martin, Sonja, Giri, Pratyush, Scholl, Sebastian, Topp, Max S, Jung, Wolfram, Vucinic, Vladan, Beck, Hans-Joachim, Kerkhoff, Andrea, Unger, Benjamin, Rank, Andreas, Schroers, Roland, zum Büschenfelde, Christian Meyer, de Wit, Maike, Trautmann-Grill, Karolin, Kamper, Peter, Molin, Daniel, Kreissl, Stefanie, Kaul, Helen, von Tresckow, Bastian, Borchmann, Sven, Behringer, Karolin, Fuchs, Michael, Rosenwald, Andreas, Klapper, Wolfram, Eich, Hans-Theodor, Baues, Christian, Zomas, Athanasios, Hallek, Michael, Dietlein, Markus, Kobe, Carsten, and Diehl, Volker

Published
2024
Full Text
View/download PDF

10. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial.

Author

Starreveld, Daniëlle EJ, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus JW, Habers, G Esther A, Bosch, Jos A, Janus, Cécile PM, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik WA, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline MA

Subjects
cancer-related fatigue, circadian rhythms, light therapy, randomized controlled trial, sleep, Clinical Research, Depression, Rehabilitation, Rare Diseases, Lymphoma, Cancer, Clinical Trials and Supportive Activities, Behavioral and Social Science, Sleep Research, Hematology, Mental Health, Oncology and Carcinogenesis
Abstract

PurposeTo evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.MethodsWe randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.ResultsThere were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.ConclusionsBWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

13. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Author

Driessen, Julia, Kersten, Marie José, Visser, Lydia, van den Berg, Anke, Tonino, Sanne H., Zijlstra, Josée M., Lugtenburg, Pieternella J., Morschhauser, Franck, Hutchings, Martin, Amorim, Sandy, Gastinne, Thomas, Nijland, Marcel, Zwezerijnen, Gerben J. C., Boellaard, Ronald, de Vet, Henrica C. W., Arens, Anne I. J., Valkema, Roelf, Liu, Roberto D. K., Drees, Esther E. E., de Jong, Daphne, Plattel, Wouter J., and Diepstra, Arjan

Published
2022
Full Text
View/download PDF

15. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours

Author

Nanni, Cristina, Kobe, Carsten, Baeßler, Bettina, Baues, Christian, Boellaard, Ronald, Borchmann, Peter, Buck, Andreas, Buvat, Irène, Chapuy, Björn, Cheson, Bruce D, Chrzan, Robert, Cottereau, Ann-Segolene, Dührsen, Ulrich, Eikenes, Live, Hutchings, Martin, Jurczak, Wojciech, Kraeber-Bodéré, Françoise, Lopci, Egesta, Luminari, Stefano, MacLennan, Steven, Mikhaeel, N George, Nijland, Marcel, Rodríguez-Otero, Paula, Treglia, Giorgio, Withofs, Nadia, Zamagni, Elena, Zinzani, Pier Luigi, Zijlstra, Josée M, Herrmann, Ken, and Kunikowska, Jolanta

Published
2023
Full Text
View/download PDF

17. Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma

Author

Eertink, Jakoba J., Zwezerijnen, Gerben J. C., Wiegers, Sanne E., Pieplenbosch, Simone, Chamuleau, Martine E. D., Lugtenburg, Pieternella J., de Jong, Daphne, Ylstra, Bauke, Mendeville, Matias, Dührsen, Ulrich, Hanoun, Christine, Hüttmann, Andreas, Richter, Julia, Klapper, Wolfram, Jauw, Yvonne W. S., Hoekstra, Otto S., de Vet, Henrica C. W., Boellaard, Ronald, and Zijlstra, Josée M.

Published
2023
Full Text
View/download PDF

21. Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.

Author

Ferrández, Maria C., Golla, Sandeep S.V., Eertink, Jakoba J., Wiegers, Sanne E., Zwezerijnen, Gerben J.C., Heymans, Martijn W., Lugtenburg, Pieternella J., Kurch, Lars, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Barrington, Sally F., Mikhaeel, N. George, Ceriani, Luca, Zucca, Emanuele, Czibor, Sándor, Györke, Tamás, Chamuleau, Martine E.D., Zijlstra, Josée M., and Boellaard, Ronald

Published
2024
Full Text
View/download PDF

22. Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma.

Author

Maas, Carolien C. H. M., van Klaveren, David, Durmaz, Müjde, Visser, Otto, Issa, Djamila E., Posthuma, Eduardus F. M., Zijlstra, Josée M., Chamuleau, Martine E. D., Lugtenburg, Pieternella J., Kersten, Marie José, and Dinmohamed, Avinash G.

Subjects
DIFFUSE large B-cell lymphomas, POSITRON emission tomography
Abstract

First-line treatment for advanced-stage diffuse large B-cell lymphoma (DLBCL) typically involves 6x R-CHOP21 or 6x R-CHOP21 with two additional rituximab administrations (6x R-CHOP21 + 2 R). In contemporary practice, this treatment choice might be guided by interim PET scan results. This nationwide, population-based study investigates the comparative effectiveness of these treatment regimens in an era where interim PET-guided treatment decisions were not standard practice. Utilizing the Netherlands Cancer Registry, we identified 1577 adult patients diagnosed with advanced-stage DLBCL between 2014–2018 who completed either 6x R-CHOP21 (43%) or 6x R-CHOP21 + 2 R (57%). We used propensity scores to assess differences in event-free survival (EFS) and overall survival (OS). At five years, EFS (hazard ratio of 6x R-CHOP21 + 2 R versus 6x R-CHOP21 [HR] = 0.89; 95% confidence interval [CI], 0.72–1.09) and OS (HR = 0.93; 95% CI, 0.73–1.18) were not significantly different between both regimens. In exploratory risk-stratified analysis according to the International Prognostic Index (IPI), high-IPI patients (i.e., scores of 4-5) benefit most from 6x R-CHOP21 + 2 R (5-year absolute risk difference of EFS = 16.8%; 95% CI, −0.4%−34.1% and OS = 12.1%; 95% CI, −5.4–29.6%). Collectively, this analysis reveals no significant differences on average in EFS and OS between the two treatments. However, the potential benefits for high-risk patients treated with 6x R-CHOP21 + 2 R underscore the need for future research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.

Author

Boellaard, Ronald, Buvat, Irène, Nioche, Christophe, Ceriani, Luca, Cottereau, Anne-Ségolène, Guerra, Luca, Hicks, Rodney J., Kanoun, Salim, Kobe, Carsten, Loft, Annika, Schöder, Heiko, Versari, Annibale, Voltin, Conrad-Amadeus, Zwezerijnen, Gerben J.C., Zijlstra, Josée M., Mikhaeel, N. George, Gallamini, Andrea, El-Galaly, Tarec C., Hanoun, Christine, and Chauvie, Stephane

Published
2024
Full Text
View/download PDF

24. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Author

Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M., Vermaat, Joost S.P., Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F., Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G., and Goy, Andre

Published
2022
Full Text
View/download PDF

27. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection

Author

Sobesky, Sophia, Mammadova, Laman, Cirillo, Melita, Drees, Esther E.E., Mattlener, Julia, Dörr, Helge, Altmüller, Janine, Shi, Zhiyuan, Bröckelmann, Paul J., Weiss, Jonathan, Kreissl, Stefanie, Sasse, Stephanie, Ullrich, Roland T., Reinke, Sarah, Klapper, Wolfram, Gerhard-Hartmann, Elena, Rosenwald, Andreas, Roemer, Margaretha G.M., Nürnberg, Peter, Hagenbeek, Anton, Zijlstra, Josée M., Pegtel, Dirk Michiel, Engert, Andreas, Borchmann, Peter, von Tresckow, Bastian, and Borchmann, Sven

Published
2021
Full Text
View/download PDF

28. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

Author

Brink, Mirian, Kahle, Xaver U., Vermaat, Joost S.P., Zijlstra, Josee M., Chamuleau, Martine, Kersten, Marie José, Durmaz, Müjde, Plattel, Wouter J., Lugtenburg, Pieternella J., Stevens, Wendy, Mous, Rogier, de Vries, Elisabeth G.E., van der Poel, Marjolein W.M., Panday, Prashant V. Nannan, Huls, Gerwin, van Meerten, Tom, and Nijland, Marcel

Published
2021
Full Text
View/download PDF

29. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

Author

Kreissl, Stefanie, Goergen, Helen, Buehnen, Ina, Kobe, Carsten, Moccia, Alden, Greil, Richard, Eichenauer, Dennis A, Zijlstra, Josée M, Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S, Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kühnhardt, Dagmar, Ostermann, Helmut, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas, and Borchmann, Peter

Published
2021
Full Text
View/download PDF

30. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)

Author

Gillessen, Sarah, Plütschow, Annette, Fuchs, Michael, Markova, Jana, Greil, Richard, Topp, Max S, Meissner, Julia, Zijlstra, Josée M, Eichenauer, Dennis A, Bröckelmann, Paul J, Diehl, Volker, Borchmann, Peter, Engert, Andreas, and von Tresckow, Bastian

Published
2021
Full Text
View/download PDF

31. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Author

Borchmann, Peter, Plütschow, Annette, Kobe, Carsten, Greil, Richard, Meissner, Julia, Topp, Max S, Ostermann, Helmut, Dierlamm, Judith, Mohm, Johannes, Thiemer, Julia, Sökler, Martin, Kerkhoff, Andrea, Ahlborn, Miriam, Halbsguth, Teresa V, Martin, Sonja, Keller, Ulrich, Balabanov, Stefan, Pabst, Thomas, Vogelhuber, Martin, Hüttmann, Andreas, Wilhelm, Martin, Zijlstra, Josée M, Moccia, Alden, Kuhnert, Georg, Bröckelmann, Paul J, von Tresckow, Bastian, Fuchs, Michael, Klimm, Beate, Rosenwald, Andreas, Eich, Hans, Baues, Christian, Marnitz, Simone, Hallek, Michael, Diehl, Volker, Dietlein, Markus, and Engert, Andreas

Published
2021
Full Text
View/download PDF

32. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., Schaapveld, Michael, Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., and Schaapveld, Michael

Published
2024

33. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., Te Boome, Liane C.J., Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., Schaapveld, Michael, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., Te Boome, Liane C.J., Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., and Schaapveld, Michael

Abstract

PURPOSEFemale Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages.METHODSWe assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals between 1975 and 2008. We calculated standardized incidence ratios, absolute excess risks, and cumulative incidences. Doxorubicin exposure was analyzed using multivariable Cox regression analyses.RESULTSAfter a median follow-up of 21.6 years (IQR, 15.8-27.1 years), 252 women had developed invasive BC or ductal carcinoma in situ. The 30-year cumulative incidence was 20.8% (95% CI, 18.2 to 23.4). Survivors treated with a cumulative doxorubicin dose of >200 mg/m2 had a 1.5-fold increased BC risk (95% CI, 1.08 to 2.1), compared with survivors not treated with doxorubicin. BC risk increased 1.18-fold (95% CI, 1.05 to 1.32) per additional 100 mg/m2 doxorubicin (Ptrend =.004). The risk increase associated with doxorubicin (yes v no) was not modified by age at first treatment (hazard ratio [HR]age <21 years, 1.5 [95% CI, 0.9 to 2.6]; HRage ≥21 years, 1.3 [95% CI, 0.9 to 1.9) or chest RT (HRwithout mantle/axillary field RT, 1.9 [95% CI, 1.06 to 3.3]; HRwith mantle/axillary field RT, 1.2 [95% CI, 0.8 to 1.8]).CONCLUSIONThis study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.

Published
2024

34. Towards IVDR‐compliance by implementing quality control steps in a quantitative extracellular vesicle‐miRNA liquid biopsy assay for response monitoring in patients with classic Hodgkin lymphoma.

Author

Drees, Esther E. E., Groenewegen, Nils J., Verkuijlen, Sandra A. W. M., van Eijndhoven, Monique A. J., Ramaker, Jip, Veenstra, Pepijn, Hussain, Mirjam, Groothuis‐Oudshoorn, Catharina G. M., de Jong, Daphne, Zijlstra, Josée M., de Rooij, Johan, and Pegtel, D. Michiel

Subjects
HODGKIN'S disease, QUALITY control, PATIENT monitoring, EXTRACELLULAR vesicles, BIOPSY
Abstract

Previously, we showed that quantification of lymphoma‐associated miRNAs miR‐155‐5p, ‐127‐3p and let‐7a‐5p levels in plasma extracellular vesicles (EVs) report treatment response in patients with classic Hodgkin lymphoma (cHL). Prior to clinical implementation, quality control (QC) steps and validation are required to meet international regulatory standards. Most published EV‐based diagnostic assays have yet to meet these requirements. In order to advance the assay towards regulatory compliance (e.g., IVDR 2017/746), we incorporated three QC steps in our experimental EV‐miRNA quantitative real‐time reverse‐transcription PCR (q‐RT‐PCR) assay in an ISO‐13485 certified quality‐management system (QMS). Liposomes encapsulated with a synthetic (nematode‐derived) miRNA spike‐in controlled for EV isolation by automated size‐exclusion chromatography (SEC). Additional miRNA spike‐ins controlled for RNA isolation and cDNA conversion efficiency. After deciding on quality criteria, in total 107 out of 120 samples from 46 patients passed QC. Generalized linear mixed‐effect modelling with bootstrapping determined the diagnostic performance of the quality‐controlled data at an area under the curve (AUC) of 0.84 (confidence interval [CI]: 0.76–0.92) compared to an AUC of 0.87 (CI: 0.80–0.94) of the experimental assay. After the inclusion of QC steps, the accuracy of the assay was determined to be 78.5% in predicting active disease status in cHL patients during treatment. We demonstrate that a quality‐controlled plasma EV‐miRNA assay is technically robust, taking EV‐miRNA as liquid biopsy assay an important step closer to clinical evaluation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Author

Kalakonda, Nagesh, Maerevoet, Marie, Cavallo, Federica, Follows, George, Goy, Andre, Vermaat, Joost S P, Casasnovas, Olivier, Hamad, Nada, Zijlstra, Josée M, Bakhshi, Sameer, Bouabdallah, Reda, Choquet, Sylvain, Gurion, Ronit, Hill, Brian, Jaeger, Ulrich, Sancho, Juan Manuel, Schuster, Michael, Thieblemont, Catherine, De la Cruz, Fátima, Egyed, Miklos, Mishra, Sourav, Offner, Fritz, Vassilakopoulos, Theodoros P, Warzocha, Krzysztof, McCarthy, Daniel, Ma, Xiwen, Corona, Kelly, Saint-Martin, Jean-Richard, Chang, Hua, Landesman, Yosef, Joshi, Anita, Wang, Hongwei, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Van Den Neste, Eric, and Canales, Miguel A

Published
2020
Full Text
View/download PDF

37. Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial

Author

van der Hout, Anja, van Uden-Kraan, Cornelia F, Holtmaat, Karen, Jansen, Femke, Lissenberg-Witte, Birgit I, Nieuwenhuijzen, Grard A P, Hardillo, José A, Baatenburg de Jong, Robert J, Tiren-Verbeet, Nicolette L, Sommeijer, Dirkje W, de Heer, Koen, Schaar, Cees G, Sedee, Robert-Jan E, Bosscha, Koop, van den Brekel, Michiel W M, Petersen, Japke F, Westerman, Matthijs, Honings, Jimmie, Takes, Robert P, Houtenbos, Ilse, van den Broek, Wim T, de Bree, Remco, Jansen, Patricia, Eerenstein, Simone E J, Leemans, C René, Zijlstra, Josée M, Cuijpers, Pim, van de Poll-Franse, Lonneke V, and Verdonck-de Leeuw, Irma M

Published
2020
Full Text
View/download PDF

39. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M., additional, Aleman, Berthe M.P., additional, Lugtenburg, Pieternella J., additional, Rademakers, Saskia E., additional, de Weijer, Roel J., additional, Schippers, Maaike G.A., additional, Ta, Bastiaan D.P., additional, Plattel, Wouter J., additional, Zijlstra, Josée M., additional, van der Maazen, Richard W.M., additional, Nijziel, Marten R., additional, Ong, Francisca, additional, Schimmel, Erik C., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Böhmer, Lara H., additional, Muller, Karin, additional, Koene, Harry R., additional, te Boome, Liane C.J., additional, Bilgin, Yavuz M., additional, de Jongh, Eva, additional, Janus, Cécile P.M., additional, van Leeuwen, Flora E., additional, and Schaapveld, Michael, additional

Published
2024
Full Text
View/download PDF

43. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Author

Fuchs, Michael, primary, Jacob, Anne Sophie, additional, Kaul, Helen, additional, Kobe, Carsten, additional, Kuhnert, Georg, additional, Pabst, Thomas, additional, Greil, Richard, additional, Bröckelmann, Paul J., additional, Topp, Max S., additional, Just, Marianne, additional, Hertenstein, Bernd, additional, Soekler, Martin, additional, Vogelhuber, Martin, additional, Zijlstra, Josée M., additional, Keller, Ulrich Bernd, additional, Krause, Stefan W., additional, Dührsen, Ulrich, additional, Meissner, Julia, additional, Viardot, Andreas, additional, Eich, Hans-Theodor, additional, Baues, Christian, additional, Diehl, Volker, additional, Rosenwald, Andreas, additional, Buehnen, Ina, additional, von Tresckow, Bastian, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Eichenauer, Dennis A., additional

Published
2023
Full Text
View/download PDF

48. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Author

Borchmann, Peter, Goergen, Helen, Kobe, Carsten, Lohri, Andreas, Greil, Richard, Eichenauer, Dennis A, Zijlstra, Josée M, Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Hüttmann, Andreas, Dierlamm, Judith, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S, Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kühnhardt, Dagmar, Ostermann, Helmut, Schmitz, Norbert, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Kuhnert, Georg, Diehl, Volker, Dietlein, Markus, and Engert, Andreas

Published
2017
Full Text
View/download PDF

49. No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study

Author

Geerdes, Emma E., primary, Durmaz, Müjde, additional, Lugtenburg, Pieternella J., additional, Chamuleau, Martine E. D., additional, Visser, Otto, additional, Issa, Djamila E., additional, Brouwer, Rolf E., additional, Posthuma, Eduardus F. M., additional, Zijlstra, Josée M., additional, Kersten, Marie José, additional, and Dinmohamed, Avinash G., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results